ArticleJournal of asthma and allergy2020
Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs.
Article in Journal of asthma and allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 59 citations in OpenAlex.
- Real-World Effectiveness of Mepolizumab Initiation in Treating Asthma and Concurrent Chronic Obstructive Pulmonary Disease in the US.Pulmonary therapy · 2026Article
- Clinical Remission is Achievable for Adult Patients with Severe Asthma Receiving Mepolizumab: A European Retrospective Chart Review.Advances in therapy · 2026Article
- Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma.The journal of allergy and clinical immunology. Global · 2026Article
- Recent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma.Antibodies (Basel, Switzerland) · 2025Review
- Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years.ERJ open research · 2025Article
- Improving patient outcomes: Mepolizumab's impact in IL-5-mediated diseases.Lung India : official organ of Indian Chest Society · 2025Article
- Healthcare Resource Utilisation and Costs of Mepolizumab Initiation: A 5-Year National Cohort Analysis.Allergy · 2025Article
- Effectiveness of anti-IL-5/5Rα biologics in severe asthma in real-world studies: a systematic review and meta-analysis.ERJ open research · 2025Article
- Prospective REALITI-A Study: 2-Year Real-World Benefits of Mepolizumab in Severe Asthma.CHEST pulmonary · 2025Article
- Biologics in severe asthma: a state-of-the-art review.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- COMMENT ON MODEL INPUTS AND ASSUMPTIONS FOR THE COST-MINIMIZATION MODEL USED TO COMPARE COST OF BIOLOGICS IN SEVERE ASTHMA.Journal of managed care & specialty pharmacy · 2024Article
- THE AUTHORS RESPOND.Journal of managed care & specialty pharmacy · 2024Article
- Efficacy and Safety of Mepolizumab in the Management of Severe Eosinophilic Asthma: A Systematic Review.Cureus · 2023Review
- A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.Journal of managed care & specialty pharmacy · 2023Article
- Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study).Journal of asthma and allergy · 2023Article
- A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma.Advances in therapy · 2022Article
- Temporal Dynamics of the Nasopharyngeal Microbiome and its Relationship with Childhood Asthma Exacerbation.Microbiology spectrum · 2022Article
- From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.Allergy · 2022Review
- TThe Journal of allergy and clinical immunology · 2022Article
- Critical evaluation of asthma biomarkers in clinical practice.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleResults from clinical trials in patients with severe eosinophilic asthma have demonstrated that mepolizumab is well tolerated and is associated with improved asthma control as evidenced by reductions in both exacerbations and maintenance oral corticosteroid use, and improvements in lung function, asthma control, and quality of life. However, real-world data are lacking on the impact of mepolizumab treatment.
objectiveTo assess the effect of mepolizumab treatment on the rate of asthma exacerbations and asthma exacerbation-related costs in a real-world setting.
methodsThis retrospective cohort study (GSK ID: 209017; HO-18-19168) analyzed data from patients with severe asthma ≥12 years of age at mepolizumab treatment initiation (index date) with ≥12 months pre- (baseline) and post-index (follow-up) data from a commercial claims database (patients were identified from November 1, 2015 to March 31, 2017). Asthma exacerbations (primary objective) and asthma exacerbation-related costs (secondary objective) in the baseline and follow-up periods were compared. Other analyses included the number of mepolizumab administrations and the use of concomitant asthma medications.
resultsData were analyzed from 346 patients. Mepolizumab significantly reduced the proportion of patients with any exacerbation and exacerbations requiring hospitalization, compared with baseline. Significant reductions in the rate of all exacerbations of 38.4% (from 2.68 to 1.65 events/patient/year;
conclusionThis study confirms the clinical benefit observed in previous mepolizumab clinical trials and demonstrates that mepolizumab is effective in a real-world setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.